(PharmaNewsWire.Com, September 19, 2018 ) According to a new study published by Polaris Market Research the global erectile dysfunction drugs market is anticipated to reach USD 2.63 billion by 2025. Request for Sample of This Research Report @ https://bit.ly/2NXzatD
Top Key Players:-
Bayer AG Pfizer Eli Lilly & Co. Vivus, Inc. S.K. Chemicals Co. Ltd. Dong-A Pharmaceutical Co. Ltd Meda Pharmaceuticals Apricus Biosciences
According to a new study published by Polaris Market Research the global erectile dysfunction drugs market is anticipated to reach USD 2.63 billion by 2025. Impotence, also known as erectile dysfunction is the condition of sexual dysfunction where, during the sexual intercourse, men cannot maintain the erection. According to World Health Organization statement, for the emotional, physical and wellbeing of the individual, and to the economic and social development of countries and communities, sexual health is a fundamental thing. Erectile dysfunction affects the quality of life for both partners and patients and is connected with relationship difficulties.
Erectile dysfunction is generally an age-related condition but can also be triggered by psychological factors. Cardiovascular diseases such as high blood pressure, clogged arteries etc., diabetes, hormonal insufficiency, chronic kidney disease, multiple sclerosis, injury to the penis, bladder, and pelvis, and neurological issues are the common factor which can cause erectile dysfunction. Moreover, sedentary lifestyle, smoking, excessive alcohol intake, obesity and consumption of drugs such as, antihypertensive drugs, antidepressant, recreational drugs, and psychotropic drugs are some other factors which are significantly contributing towards erectile dysfunction. Exercise, pharmacotherapy, well balanced and maintain lifestyle, penis implants, erection devices, and injections into penis are current treatment available to cure erectile dysfunction. Currently, oral PDE5 (phosphodiesterase type 5 inhibitors) is the first line drug therapy prescribed by physicians for erectile dysfunction.
The availability of oral drugs globally, and rising awareness about erectile dysfunction and sexual diseases is resulting in significant adoption of treatment globally. Moreover, rising number of referrals to secondary care and primary care consultations is expected to propel the growth of erectile dysfunctions drugs market over the forecast period. The increasing elderly population and high rate of chronic diseases such as kidney failure, diabetes, hypertension, hormonal imbalance, and neurological disorders are increasing demand for erectile dysfunction drugs globally.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including: